DOCSLIB.ORG

Progressive Multifocal Leukoencephalopathy and the Spectrum of JC Virus-​Related Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progressive Multifocal Leukoencephalopathy and the Spectrum of JC Virus-​Related Disease REVIEWS Progressive multifocal leukoencephalopathy and the spectrum of JC virus- related disease Irene Cortese 1 ✉ , Daniel S. Reich 2 and Avindra Nath3 Abstract | Progressive multifocal leukoencephalopathy (PML) is a devastating CNS infection caused by JC virus (JCV), a polyomavirus that commonly establishes persistent, asymptomatic infection in the general population. Emerging evidence that PML can be ameliorated with novel immunotherapeutic approaches calls for reassessment of PML pathophysiology and clinical course. PML results from JCV reactivation in the setting of impaired cellular immunity, and no antiviral therapies are available, so survival depends on reversal of the underlying immunosuppression. Antiretroviral therapies greatly reduce the risk of HIV-related PML, but many modern treatments for cancers, organ transplantation and chronic inflammatory disease cause immunosuppression that can be difficult to reverse. These treatments — most notably natalizumab for multiple sclerosis — have led to a surge of iatrogenic PML. The spectrum of presentations of JCV- related disease has evolved over time and may challenge current diagnostic criteria. Immunotherapeutic interventions, such as use of checkpoint inhibitors and adoptive T cell transfer, have shown promise but caution is needed in the management of immune reconstitution inflammatory syndrome, an exuberant immune response that can contribute to morbidity and death. Many people who survive PML are left with neurological sequelae and some with persistent, low-level viral replication in the CNS. As the number of people who survive PML increases, this lack of viral clearance could create challenges in the subsequent management of some underlying diseases. Progressive multifocal leukoencephalopathy (PML) is for multiple sclerosis. Taken together, HIV, lymphopro- a rare, debilitating and often fatal disease of the CNS liferative disease and multiple sclerosis account for the caused by JC virus (JCV). JCV commonly establishes majority of PML cases. asymptomatic, lifelong persistent or latent infection in No antiviral therapies are available for JCV infection 1Neuroimmunology Clinic, National Institute of the general population but, in patients with prolonged or PML, and survival depends on reversal of the under- Neurological Disorders and and profound compromise of cellular immunity, JCV lying immunosuppression. Emerging evidence indi- Stroke, National Institutes of can reactivate from sites of latency and undergo sequen- cates that when immunosuppression cannot be readily Health, Bethesda, MD, USA. tial genomic rearrangements. This intrahost viral evo- reversed, novel immunotherapeutic strategies that are 2Translational Neuroradiology lution allows an otherwise benign virus to cause lytic designed to augment antiviral immune responses could Section, National Institute of infection of CNS glial cells and thus PML. be of benefit. In light of these exciting developments, Neurological Disorders and Stroke, National Institutes of Before the AIDS pandemic, PML was a rare compli- we provide here an overview of the pathobiology of Health, Bethesda, MD, USA. cation in patients with immune compromise related to JCV infection and PML and discuss the evolving clin- 3Section of Infections of the lymphoproliferative disease. The AIDS pandemic led ical presentation of PML and atypical JCV-related CNS Nervous System, National to the first surge in occurrence of PML. The introduction manifestations. We then review the novel immunother- Institute of Neurological of highly effective antiretroviral therapies decreased the apeutic approaches to the treatment of this disease that Disorders and Stroke, incidence of PML in AIDS, although HIV remains offer some promise for increased survival. National Institutes of Health, Bethesda, MD, USA. the single greatest contributor to the total number of JCV and disease mechanisms ✉e- mail: corteseir@ PML cases. In the past decade, a second, smaller surge ninds.nih.gov has been seen, associated with the development of mod- An ancient and ubiquitous virus. JCV was the first https://doi.org/10.1038/ ern treatments for cancers, organ transplantation and of two human polyomaviruses to be isolated in 1971 s41582-020-00427- y chronic inflammatory disease, most notably natalizumab (REF.1). The family Polyomaviridae has since expanded, NATURE REVIEWS | NEUROLOGY VOLUME 17 | JANUARY 2021 | 37 REVIEWS Key points Structure and genome. Polyomaviruses are small, non- enveloped, double- stranded DNA viruses. Entry into • Progressive multifocal leukoencephalopathy (PML) is a rare, debilitating and often host cells occurs primarily via attachment of viral parti- fatal disease of the CNS caused by JC virus (JCV). cles to sialic acid moieties, followed by clathrin-mediated • JCV establishes asymptomatic, lifelong persistent or latent infection in immune endocytosis21. In vitro studies have shown that viral entry competent hosts, but impairment of cellular immunity can lead to reactivation of into glial cells is facilitated by the 5-HT serotonin recep- JCV and PML. 2A tor. Viral replication, protein synthesis and assembly • PML most commonly occurs in patients with HIV infection or lymphoproliferative of viral particles rely on host cellular machinery21. disease and in patients who are receiving natalizumab for treatment of multiple The circular genome of JCV contains two coding sclerosis. regions: the early viral gene region, which encodes reg- • The clinical phenotype of PML varies and is shaped primarily by the host immune ulatory proteins (large and small tumour antigens), and response; changes in the treatment of underlying diseases associated with PML have changed phenotypes over time. the late viral gene region, which principally encodes structural proteins (VP1, VP2 and VP3) and the acces- • Other clinical manifestations of JCV infection have been described, including granule 21 cell neuronopathy. sory regulatory protein agnoprotein . The early viral gene region and the late viral gene region are separated • Survival of PML depends on reversal of the underlying immunosuppression; emerging by a regulatory non- coding control region (NCCR)21, immunotherapeutic strategies include use of checkpoint inhibitors and adoptive T cell transfer. which contains the origin of replication and regulatory regions for early and late transcription. Importantly, this region includes host cell- specific DNA and tran- and 11 additional human viruses of this family have scription factor-binding sites. The NCCR is the region of been identified in the past decade2. The number and greatest sequence diversity and determines the efficiency variety of human polyomaviruses reflect their ability to of viral replication and cellular tropism22–24. Thus, host propagate at low levels without causing disease and cell permissiveness is determined at the transcriptional to evade clearance by the immune system; most poly- level by the expression of specific regulatory proteins, omaviruses establish asymptomatic infection in healthy among them the nuclear factor 1 (NFI) family and hosts and are pathogenic only in the setting of severe NFIX (which is highly expressed in brain), rather than immunosuppression3. by the expression of cell- surface receptors that mediate JCV is an ancient, ubiquitous virus that seems to viral entry25. have co- evolved with human populations2,4,5. JCV Sequencing of viral isolates from healthy and dis- infection typically occurs in childhood via horizon- eased individuals has demonstrated that JCV found in tal transmission through long- term cohabitation, urine has a stable genetic architecture with conserved most commonly from parent to child6. Seroconversion sequence blocks and only modest genomic variation of increases with age and reaches ~60–80% by the age the NCCR. This stable viral variant has been referred of 70 years7–11. Transmission is thought to occur via to as the archetype virus and is the transmissible form person- to- person contact and contaminated surfaces, found in the environment12,19,26. Archetype virus repli- food and water12,13, and the virus enters through the cates poorly in glial cells27 and is rarely detected in the oropharynx. Consistent with this notion, JCV can cerebrospinal fluid (CSF) of individuals with PML28. be isolated from tonsil and gut lymphatic tissue of Instead, viral isolates from the brain, CSF and blood infected individuals, which might be sites of primary of patients with PML most commonly include a com- infection14,15. plex, patient- specific mixture of JCV quasispecies with Haematogenous spread mediates infection of sec- highly variable genetic rearrangement of the NCCR; ondary sites, including kidney, bone marrow, lymphoid these variants are referred to as prototype viruses or tissue and possibly brain. Within bone marrow and rearranged variants. Notably, despite substantial dif- lymphoid tissue, precursor B cells, CD34+ haematopoi- ferences in the NCCR, only one major VP1 serotype etic progenitor cells and tonsillar stromal cells can all exists that is indistinguishable between archetype and harbour JCV16. True viral latency — defined by detec- prototype virus29; these variants can be identified only tion of transcriptionally inactive virus — can be estab- by sequencing. lished at secondary sites in immunocompetent hosts, and JCV infection of uroepithelium commonly results Intrahost viral evolution. Rearranged NCCRs do not in persistent infection, which involves asymptomatic carry simple point mutations but rather carry
Load more

Recommended publications
  • Lesson of the Month (2)
    CMJ0906-Pande_LoM.qxd 11/17/09 9:58 AM Page 626 7 Nelson RL, Persky V, Davis F, Becker E. Risk of disease in siblings Address for correspondence: Dr SD Pande, Changi of patients with hereditary haemochromatosis. Digestion General Hospital, 2 Simei Street 3, Singapore 529889. 2001;64:120–4. Email: [email protected] 8 Reyes M, Dunet DO, Isenberg KB, Trisoloni M, Wagener DK. Family based detection for hereditary haemochromatosis. J Genet Couns 2008;17:92–100. Clinical Medicine 2009, Vol 9, No 6: 626–7 lesson of the month (2) negative. He was treated empirically with intravenous acyclovir and ceftriaxone for three days before all these culture results were Considering syphilis in aseptic meningitis available. He subsequently made a very good recovery. As part of a screen for other causes of aseptic meningitis, syphilis serology was Clinicians need to consider syphilis in the differential requested which was positive for immunoglobulin M (IgM) anti- diagnosis of macular or papular rashes with body and venereal disease research laboratory (VDRL) was posi- neurological conditions, particularly aseptic meningitis, tive with a titre of 1:64. This was confirmed with a repeat sample. as early diagnosis and treatment lead to a better The patient therefore continued treatment with ceftriaxone for prognosis. two weeks. As part of contact tracing his wife, who was asympto- matic, was screened for syphilis and was found to have positive serology. She was treated with a standard regime of benzathine penicillin. On follow-up, both showed good responses serologi- cally and both patients tested negative for HIV. Lesson In March 2007 a 45-year-old heterosexual male presented to the Discussion medical assessment unit with a three-week history of headaches, occasional vomiting and more recent confusion.
    [Show full text]
  • West Nile Virus Aseptic Meningitis and Stuttering in Woman
    LETTERS Author affi liation: University of the Punjab, Address for correspondence: Muhammad having received multiple mosquito Lahore, Pakistan Idrees, Division of Molecular Virology and bites during the preceding weeks. Molecular Diagnostics, National Centre of At admission, she had a DOI: 10.3201/eid1708.100950 Excellence in Molecular Biology, University temperature of 101.3°F, pulse rate of Punjab, 87 West Canal Bank Rd, Thokar of 92 beats/min, blood pressure of References Niaz Baig, Lahore 53700, Pakistan; email: 130/80 mm Hg, and respiratory rate of 1. Idrees M, Lal A, Naseem M, Khalid M. [email protected] 16 breaths/min. She appeared mildly High prevalence of hepatitis C virus infec- ill but was alert and oriented with no tion in the largest province of Pakistan. nuchal rigidity, photophobia, rash, or J Dig Dis. 2008;9:95–103. doi:10.1111/ j.1751-2980.2008.00329.x limb weakness. Results of a physical 2. Martell M, Esteban JI, Quer J, Genesca examination were unremarkable, and J, Weiner A, Gomez J. Hepatitis C virus results of a neurologic examination circulates as a population of different but were notable only for stuttering. closely related genomes: quasispecies na- ture of HCV genome distribution. J Virol. Laboratory test results included a West Nile Virus 3 1992;66:3225–9. leukocyte count of 12,300 cells/mm 3. Jarvis LM, Ludlam CA, Simmonds P. Hep- Aseptic Meningitis (63% neutrophils, 29% lymphocytes, atitis C virus genotypes in multi-transfused 7% monocytes, 1% basophils) and individuals. Haemophilia. 1995;1(Sup- and Stuttering in pl):3–7.
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Study Protocol
    PROTOCOL SYNOPSIS A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus International Coordinating Investigator Study site(s) and number of subjects planned Approximately 450 subjects are planned at approximately 173 sites. Study period Phase of development Estimated date of first subject enrolled Q2 2015 3 Estimated date of last subject completed Q2 2018 Study design This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab (150 mg or 300 mg) versus placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. The study will be performed in adult subjects aged 18 to 70 years of age. Approximately 450 subjects receiving SOC treatment will be randomised in a 1:2:2 ratio to receive a fixed intravenous dose of 150 mg anifrolumab, 300 mg anifrolumab, or placebo every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous (IV) infusion via an infusion pump over a minimum of 30 minutes, Q4W. Subjects must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. Randomisation will be stratified using the following factors: SLE Disease Activity Index 2000 (SLEDAI-2K) score at screening (<10 points versus ≥10 points); Week 0 (Day 1) OCS dose 2(125) Revised Clinical Study Protocol Drug Substance Anifrolumab (MEDI-546) Study Code D3461C00005 Edition Number 5 Date 18 May 2016 (<10 mg/day versus ≥10 mg/day prednisone or equivalent); and results of a type 1 interferon (IFN) test (high versus low).
    [Show full text]
  • HLA-Cw6 Status Predicts Efficacy of Biologic Treatments in Psoriasis
    Global Dermatology Research Article ISSN: 2056-7863 HLA-Cw6 status predicts efficacy of biologic treatments in psoriasis patients Wayne P Gulliver1,2*, Heather Young1, Susanne Gulliver1 and Shane Randell1,2 1Newlab Clinical Research, St. John’s, NL, Canada 2Department of Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada Abstract Over the past decade, biologic therapies have been developed to treat auto-inflammatory conditions such as psoriasis. They have the advantage of better target specificity than traditional systemics such as methotrexate and cyclosporine and therefore significantly reduce side-effects and toxicity associated with wide spread systemic treatments. It has been suggested that the efficacy of biologics used in the treatment of psoriasis may be related with HLA-Cw6 status.Using HLA-Cw6 as a biomarker would therefore provide an advantage in the selection of a biologic agent for successful treatment based on a patient’s genetic makeup and thus allowing us to use HLA-Cw6 to individualize therapy for patients with moderate-to-severe psoriasis.In the present study, the HLA-Cw6 status was determined for psoriasis patients previously treated with etanercept, adalimumab, efalizumab, infliximab or ustekinumab.The success or failure rates of the biologic treatments were compared for patients with and without the HLA-Cw6 allele.The HLA-Cw6 status was significantly associated to the treatment outcomes for biologics efalizumab (no longer on the market), infliximab and ustekinumab; but not etanercept or adalimumab.These results support the use of HLA-Cw6 status as a biomarker for biologic treatment in moderate-to-severe psoriasis patients. Introduction The association appears strong and is found in anywhere from 40- 80% of cases [9], however other genes nearby may play a role that also Psoriasis vulgaris is a chronic inflammatory skin disease that contribute to the development of psoriasis.
    [Show full text]
  • Unusual Case of Progressive Multifocal Leukoencephalopathy in a Patient with Sjögren Syndrome
    Henry Ford Health System Henry Ford Health System Scholarly Commons Pathology Articles Pathology 1-15-2021 Unusual Case of Progressive Multifocal Leukoencephalopathy in a Patient With Sjögren Syndrome Ifeoma Onwubiko Kanika Taneja Nilesh S. Gupta Abir Mukherjee Follow this and additional works at: https://scholarlycommons.henryford.com/pathology_articles CASE REPORT Unusual Case of Progressive Multifocal Leukoencephalopathy in a Patient With Sjögren Syndrome Ifeoma Ndidi Onwubiko, MD, MPH, Kanika Taneja, MD, Nilesh Gupta, MD, and Abir Mukherjee, MD 03/05/2021 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= by http://journals.lww.com/amjforensicmedicine from Downloaded 84% neutrophils; glucose, 71 mmol/L; protein, 183 g/dL with neg- Abstract: Progressive multifocal leukoencephalopathy (PML) is a rare Downloaded ative cultures and no malignant cells on cytology). Hepatitis C anti- demyelinating disease caused by reactivation of John Cunningham virus af- body screen was negative. Immunoglobin G antibodies to Sjögren fecting typically subcortical and periventricular white matter of immunocom- syndrome–related antigen A and anti–Sjögren syndrome-related from promised hosts (human immunodeficiency virus infection, hematologic antigen B were positive. Thyroglobulin antibodies and antinuclear http://journals.lww.com/amjforensicmedicine malignancies). Cerebral hemispheric white matter is most commonly affected antibodies were elevated. Autoimmune serological tests for other by lytic
    [Show full text]
  • The Challenge of Drug-Induced Aseptic Meningitis
    REVIEW ARTICLE The Challenge of Drug-Induced Aseptic Meningitis German Moris, MD; Juan Carlos Garcia-Monco, MD everal drugs can induce the development of aseptic meningitis. Drug-induced aseptic men- ingitis (DIAM) can mimic an infectious process as well as meningitides that are secondary to systemic disorders for which these drugs are used. Thus, DIAM constitutes a diagnostic and patient management challenge. Cases of DIAM were reviewed through a MEDLINE Sliterature search (up to June 1998) to identify possible clinical and laboratory characteristics that would be helpful in distinguishing DIAM from other forms of meningitis or in identifying a specific drug as the culprit of DIAM. Our review showed that nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, intravenous immunoglobulins, and OKT3 antibodies (monoclonal antibodies against the T3 receptor) are the most frequent cause of DIAM. Resolution occurs several days after drug discon- tinuation and the clinical and cerebrospinal fluid profile (neutrophilic pleocytosis) do not allow DIAM to be distinguished from infectious meningitis. Nor are there any specific characteristics associated with a specific drug. Systemic lupus erythematosus seems to predispose to NSAID-related meningi- tis. We conclude that a thorough history on prior drug intake must be conducted in every case of meningitis, with special focus on those aforementioned drugs. If there is a suspicion of DIAM, a third- generation cephalosporin seems a reasonable treatment option until cerebrospinal fluid cultures are available. Arch Intern Med. 1999;159:1185-1194 Several drugs can induce meningitis, re- been associated with drug-induced aseptic sulting in a diagnostic and therapeutic meningitis (DIAM) (Table 1): nonsteroi- challenge.
    [Show full text]
  • Omalizumab Treatment in Severe Adult Atopic Dermatitis
    Case report Omalizumab treatment in severe adult atopic dermatitis Supitchaya Thaiwat1 and Atik Sangasapaviliya2 Summary Conventional therapies for AD include topical Atopic dermatitis (AD) is one of the most agents e.g., steroids, topical calcineurin inhibitors, common chronic skin diseases. Treatment phototherapy and oral medications e.g. azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, options include lubricants, antihistamines, and 4 corticosteroids in either topical or oral forms. prednisone, etc. Oral medications are generally Severe AD is frequently recalcitrant to these reserved for moderate to severe AD because of their medications. We reported three cases of severe systemic toxicities e.g., adrenal suppression, AD patients who had elevated of IgE levels and diabetes, renal toxicity, liver toxicity and failed to response to several prior medical myelosuppression. treatment. Omalizumab is a humanized monoclonal anti- After being treated with Omalizumab IgE antibody that binds to the IgE molecule at the (humanized monoclonal anti-IgE antibody), the high-affinity FcεRI receptor binding site. The drug patients had marked alleviation of symptoms has been approved by the Food and Drug with improved Eczema Area and Severity Index Administration for adults and adolescents (12 years of age and above) with moderate to severe persistent (EASI) and pruritic scores. No patient 5 experienced adverse effect. (Asian Pac J Allergy asthma Since AD shares a common pathologic Immunol 2011;29:357-60) mechanism, that is IgE reactivation, with asthma, omalizumab has been tested as a systemic therapy Key words: Omalizumab, IgE levels, EASI score for recalcitrant AD associated with elevated IgE levels. We reported three cases of severe AD in Introduction adults who were successfully treated with Atopic dermatitis (AD) is one of the most Omalizumab.
    [Show full text]
  • Seizures in Encephalitis
    Neurology Asia 2008; 13 : 1 – 13 REVIEW ARTICLES Seizures in encephalitis Usha Kant Misra DM, *C T Tan MD, Jayantee Kalita DM Department of Neurology, Sanjay Gandhi PGIMS, Lucknow, India; *Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia Abstract A large number of viruses can result in encephalitis. However, certain viruses are more prevalent in certain geographical regions. For example, Japanese encephalitis (JE) and dengue in South East Asia and West Nile in Middle East whereas Herpes simplex encephalitis (HSE) occurs all over the world without any seasonal or regional variation. Encephalitis can result in acute symptomatic seizures and remote symptomatic epilepsy. Risk of seizures after 20 years is 22% following encephalitis and 3% after meningitis with early seizures. Amongst the viruses, HSE is associated with most frequent and severe epilepsy. Seizures may be presenting feature in 50% because of involvement of highly epileptogenic frontotemporal cortex. Presence of seizures in HSE is associated with poor prognosis. HSE can also result in chronic and relapsing form of encephalitis and may be an aetiology factor in drug resistant epilepsy. Amongst the Flaviviruses, Japanese encephalitis is the most common and is associated with seizures especially in children. The frequency of seizures in JE is reported to be 6.9% to 46%. Associated neurocysticercosis in JE patients may aggravate the frequency and severity of seizures. Other flaviviruses such as equine, St Louis, and West Nile encephalitis can also produce seizures. In Nipah encephalitis, seizures are commoner in relapsed and late-onset encephalitis as compared to acute encephalitis (50% vs 24%). Other viruses like measles, varicella, mumps, influenza and enteroviruses may result in encephalitis and seizures.
    [Show full text]
  • Aseptic Meningitis Face Sheet
    Aseptic Meningitis Face Sheet 1. What is aseptic meningitis (AM)? - AM refers to a viral infection of the meninges (a system of membranes surrounding the brain and spinal cord). It is a fairly common disease, however, almost all cases occur as an isolated event, and outbreaks are rare. 2. Who gets AM? - Anyone can get AM but it occurs most often in children. 3. What viruses cause this form of meningitis? - Approximately half of the cases of AM in the United States are caused by common intestinal viruses (enteroviruses). Occasionally, children develop AM associated with either mumps or herpes virus infection. Mosquito-borne viruses: e.g. WNV also account for a few cases each year in Pennsylvania. In most cases, the specific virus is never identified. 4. How are viruses that cause AM spread? - In the absence of a specific laboratory diagnosis of the causative AM virus, it is difficult to implement targeted prevention measures as some are spread person-to-person while others are spread by insects. 5. What are the symptoms? - They include fever, headache, stiff neck and fatigue. Rash, sore throat and intestinal symptoms may also occur. 6. How soon do symptoms appear? - Generally appear within one week of exposure. 7. How is AM diagnosed? – The only way to diagnose AM is to collect a sample of spinal fluid through a lumbar puncture (also known as a spinal tap). 8. Is a person with AM contagious? – While some of the enteroviruses that may cause AM are potentially contagious person to person, others, such as mosquito- borne viruses, cannot be spread person to person.
    [Show full text]
  • Everything You Always Wanted to Know About Rabies Virus ♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣♣ (But Were Afraid to Ask) Benjamin M
    ANNUAL REVIEWS Further Click here to view this article's online features: t%PXOMPBEmHVSFTBT115TMJEFT t/BWJHBUFMJOLFESFGFSFODFT t%PXOMPBEDJUBUJPOT Everything You Always Wanted t&YQMPSFSFMBUFEBSUJDMFT t4FBSDILFZXPSET to Know About Rabies Virus (But Were Afraid to Ask) Benjamin M. Davis,1 Glenn F. Rall,2 and Matthias J. Schnell1,2,3 1Department of Microbiology and Immunology and 3Jefferson Vaccine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107; email: [email protected] 2Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 Annu. Rev. Virol. 2015. 2:451–71 Keywords First published online as a Review in Advance on rabies virus, lyssaviruses, neurotropic virus, neuroinvasive virus, viral June 24, 2015 transport The Annual Review of Virology is online at virology.annualreviews.org Abstract This article’s doi: The cultural impact of rabies, the fatal neurological disease caused by in- 10.1146/annurev-virology-100114-055157 fection with rabies virus, registers throughout recorded history. Although Copyright c 2015 by Annual Reviews. ⃝ rabies has been the subject of large-scale public health interventions, chiefly All rights reserved through vaccination efforts, the disease continues to take the lives of about 40,000–70,000 people per year, roughly 40% of whom are children. Most of Access provided by Thomas Jefferson University on 11/13/15. For personal use only. Annual Review of Virology 2015.2:451-471. Downloaded from www.annualreviews.org these deaths occur in resource-poor countries, where lack of infrastructure prevents timely reporting and postexposure prophylaxis and the ubiquity of domestic and wild animal hosts makes eradication unlikely. Moreover, al- though the disease is rarer than other human infections such as influenza, the prognosis following a bite from a rabid animal is poor: There is cur- rently no effective treatment that will save the life of a symptomatic rabies patient.
    [Show full text]
  • CONTENTS EDITORIAL Chronic Fatigue Syndrome
    Volume 11 Number 1 2003 CONTENTS EDITORIAL Chronic Fatigue Syndrome Guidelines 1 Kenny De Meirleir Neil McGregor Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols 7 Bruce M. Carruthers Anil Kumar Jain Kenny L. De Meirleir Daniel L. Peterson Nancy G. Klimas A. Martin Lerner Alison C. Bested Pierre Flor-Henry Pradip Joshi A. C. Peter Powles Jeffrey A. Sherkey Marjorie I. van de Sande Recent years have brought growing recognition of the need for clinical criteria for myalgic encephalomyelitis (ME), which is also called chronic fatigue syndrome (CFS). An Expert Subcommittee of Health Canada established the Terms of Refer- ence, and selected an Expert Medical Consensus Panel representing treating physi- cians, teaching faculty and researchers. A Consensus Workshop was held on March 30 to April 1, 2001 to culminate the review process and establish consen- sus for a clinical working case definition, diagnostic protocols and treatment pro- tocols. We present a systematic clinical working case definition that encourages a diagnosis based on characteristic patterns of symptom clusters, which reflect specific areas of pathogenesis. Diagnostic and treatment protocols, and a short overview of research are given to facilitate a comprehensive and integrated ap- proach to this illness. Throughout this paper, “myalgic encephalomyelitis” and “chronic fatigue syndrome” are used interchangeably and this illness is referred to as “ME/CFS.” KEYWORDS. Clinical case definition, myalgic encephalomyelitis, chronic fa- tigue syndrome, ME, CFS, diagnostic protocol, treatment protocol Monitoring a Hypothetical Channelopathy in Chronic Fatigue Syndrome: Preliminary Observations 117 Jo Nijs Christian Demanet Neil R. McGregor Pascale De Becker Michel Verhas Patrick Englebienne Kenny De Meirleir This study was aimed at monitoring of a previously suggested channelopathy in Chronic Fatigue Syndrome, and at searching for possible explanations by means of immune system characteristics.
    [Show full text]